Navigation Links
Burrill & Company Invests in Taiwan Liposome Company
Date:7/7/2009

SAN FRANCISCO and TAIPEI, Taiwan, July 7 /PRNewswire/ -- US Venture Capital firm Burrill & Company has invested in Taiwan Liposome Company (http://www.tlcbio.com), a Taiwan based company with operations in Taipei and South San Francisco. Taiwan Liposome Company ("TLC"), is a specialty pharmaceutical company with a proprietary drug delivery technology based on a lipid formulation platform.

TLC is developing and commercializing a portfolio of "super-generics" with advantageous delivery or formulation characteristics. Some of these products include TLC's lead product, ProFlow (used to treat peripheral arterial disease and diabetic neuropathy), which is currently undergoing product development and registration in Asian markets. The company's ovarian and breast cancer treatment, Lipo-Dox, is already marketed in Taiwan.

"We believe that TLC's core advantage of applying proprietary drug delivery technology to extend product lifecycles with performance improvements enables TLC to develop and commercialize new formulations of products with significant market potential," said Burrill & Company General Partner, Dr. Ann Hanham. "We are eager to see the wide roll-out of products derived from this technology to treat diseases that would otherwise be difficult to target, such as certain types of cancer," added Marietta Wu, Director, Burrill & Company.

"It is exciting and stimulating for TLC to have Burrill & Company as a new addition to our current investors. We will benefit greatly from Burrill's extensive international experience and expertise, elevating TLC to becoming a global biotechnology company," said TLC Chairman, Dr. Keelung Hong. "Having Burrill & Company on board is a strong and accredited proof of TLC's capabilities and potential, the successful closing of this round of financing will enable TLC to focus on bringing better medical solutions for patients in need," added George Yeh, President of TLC.

Burrill & Company was joined in this Series A round of financing by YFY Biotech Management Company, TaiAn Technologies Eminent VC, Boston Life Science Venture Corp., and other earlier investors. The proceeds will serve to advance the development of its lead product and prepare the company for an IPO in Taiwan.

About Taiwan Liposome Company

Incorporated in 1997, Taiwan Liposome Company is a biopharmaceutical company engaging in research, development and commercialization of proprietary drug delivery system for improving the treatment of cancer, ophthalmic conditions, and infectious diseases. TLC founded and led by renowned scientist, Dr. Keelung Hong, who has over 30 years of research and development experience in liposomes with over 100 publications. TLC also has a team of researchers, management, production experts, and advisors who are building the company into an organization recognized for its excellence in targeted delivery and rapid advancement of products through the drug development process in South San Francisco, California and Taipei.

About Burrill & Company

Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. Burrill is also the creator, sponsor and facilitator of over a dozen leading industry conferences worldwide and publisher of a range of bio-intelligence reports including the monthly Burrill Report, which tracks the progress of the global biotechnology industry and annual "State of the Industry" report the latest of which is Biotech 2009-Life Sciences: Navigating the Sea Change, the 23rd annual report on the industry. The 470-plus page book contains analysis and perspectives on the performance of the industry in 2008 and projections for 2009 and beyond. For more information, visit

http://www.burrillandco.com


'/>"/>
SOURCE Burrill & Company
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Shawn Cross Joins Burrill Merchant Banking
2. Larta Institute Partners With Burrill & Company to Present the 14th Annual Life Sciences Venture Forum
3. Burrill Merchant Banking Advises Faes Farma on Bilastine Licensing Agreement
4. Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement
5. Burrill & Company Announces Promotions
6. The 3rd Annual Burrill Personalized Medicine Meeting November 12-13, 2007 in San Francisco
7. iCardiac Selected by Top 10 Pharmaceutical Company
8. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
9. Bion Announces Approval of New U.S. Patent that Broadens Protection for the Companys Livestock Waste Environmental Treatment Processes
10. CEL-SCI Files Patent Application to Support Companys Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses
11. Solon Manufacturing Company Acquires PurFybr Brands; Adds Influenza Virus Diagnostic Swabs to Product Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
Breaking Biology Technology:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
Breaking Biology News(10 mins):